EHA 2022 | Next steps in myeloma research: MRD-driven studies, immunotherapy & approaching a cure
Benjamin Derman
• 1 Jun 2022
Benjamin Derman, MD, The University of Chicago, Chicago, IL, shares his thoughts on the most exciting ongoing research in multiple myeloma. Dr Derman speaks on the potential impact of measurable residual disease (MRD)-driven clinical trials, and on advances in CAR-T therapy and bispecific antibodies which allow patients to achieve deeper and more durable responses. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Honoraria for advisory board fees from Janssen, Sanofi, and COTA healthcare.
